The US meningococcal vaccines market is expected to grow over the forecast period due to incremental increases in MenACWY and MenB coverage rates in adolescents and young adults before the anticipated introduction of Pfizer and GSK’s pentavalent vaccines in late 2023 or 2024. Beyond this period, market growth will be driven by the uptake of pentavalent vaccines, which could significantly boost coverage for the MenB component by linking the higher coverage rates observed with the booster dose of MenACWY in adolescents (60.0% in 2021) to the suboptimal coverage rates with MenB vaccines (31.4% of 17-year-olds reported having received at least one MenB dose in 2021). However, this will depend on the strength of Advisory Committee on Immunization Practices (ACIP) recommendations. The pentavalent vaccines would also be more convenient for physicians and patients as they could reduce the total number of doses required during adolescence from four (two MenACWY + two MenB) to three (two primary doses plus a booster). 

This Datamonitor Healthcare report contains a Disease Analysis module.